FDA Approval of Andexanet Alfa Based on a Single-Arm Trial: If There Is a Villain, Who Is It?

Ann Emerg Med. 2019 Nov;74(5):725-727. doi: 10.1016/j.annemergmed.2019.05.034.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Factor Xa Inhibitors*
  • Factor Xa*
  • Hemorrhage
  • Humans
  • Recombinant Proteins

Substances

  • Factor Xa Inhibitors
  • PRT064445
  • Recombinant Proteins
  • Factor Xa